NEW YORK (GenomeWeb) – Contract research organization Helomics and molecular diagnostics firm MDNA today announced a partnership broadening access to MDNA's tests.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets. Helomics will also offer the tests in its CLIA-approved clinical laboratory.
The firms will additionally collaborate on developing, validating, and commercializing other liquid biopsy-based diagnostic tests based on MDNA's Mitomic Technology platform, which exploits unique biological characteristics of mitochondrial DNA. MDNA intends to grant Helomics a license under which Helomics will be able to offer to its pharmaceutical, diagnostic, and biotechnology clients diagnostic tests based on MDNA's technology, the firms said.
Terms of the deal were not disclosed.
"We anticipate that by leveraging the core expertise of both companies, many new diagnostic tests will be developed and commercialized that will lead to a better understanding of the uniqueness of a patient's cancer," Helomics President and CEO Gerald Vardzel Jr. said in a statement.
Helomics completed its restructuring to become a CRO and clinical products organization last month.